Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| CFM 4 | CFM 4. Group: Biochemicals. Grades: Purified. CAS No. 331458-02-7. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. |  Worldwide |
| CFM 4 | CFM 4 is a CARP-1 mimetic compound that inhibits CARP-1 binding to APC-2. It causes apoptosis and inhibition of cell growth in cancer cells. Synonyms: CFM-4; CFM 4; CFM4; 1-[(2-Chlorophenyl)methyl]-5'-phenyl-spiro[3H-indole-3,2'(3'H)-[1,3,4]thiadiazol]-2(1H)-one. Grades: ≥99% by HPLC. CAS No. 331458-02-7. Molecular formula: C22H16ClN3OS. Mole weight: 405.9. |  |
| Altenusin | Altenusin is a a biphenyl derivative with an IC50 value of 4.3±0.3 μM in the TR assay, which is isolated from the endophytic fungus Alternaria. It inhibits Src kinase with an IC50 value of 20 nM. Altenusin inhibits fibrillization of recombinant tau fragments in vitro and phosphorylation of tau in SH-SY5Y cells expressing human P301L mutant tau when used at a concentration of 10 μM. Altenusin is known to have antioxidant properties and to inhibit several enzymes, including myosin light chain kinase, sphingomyelinase, acetylcholinesterase, cFMS kinase, pp60c-SRc kinase and HIV-1 integrase. Synonyms: Alutenusin; MS 341; MS-341; MS341. Grades: ≥98%. CAS No. 31186-12-6. Molecular formula: C15H14O6. Mole weight: 290.27. | |
| DCC-2618 | DCC-2618 inhibits normal and mutant KIT kinase at the nanomol level. The targets are wt c-KIT, c-KIT mutants, PDGFR alpha, PDGFR beta, KDR and cFMS. DCC-2618 inhibits mutant KIT in GIST patient cell line (GIST T1 pKIT western Ex11 deletion) at a IC 50 of 2 nM. Deciphera's technology has identified DCC-2618 as a molecule which can be developed as second line therapy for imatinib and sunitinib resistant GIST patients with the potential to progress to frontline GIST therapy. DCC-2618 has been designed to effectively inhibit the imatinib and sunitinib-sensitive KIT juxtamembrane domain mutants (JMD) as well as secondary resistant KIT kinase-domain mutants. DCC-2618 additionally targets PDGFR alpha oncogenic mutants. Synonyms: DCC2618; DCC 2618; c-Kit-IN-1; PDGFR inhibitor 1; N-[2,5-Difluoro-4-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]phenyl]-N'-phenyl-1,1-cyclopropanedicarboxamide. Grades: >98%. CAS No. 1225278-16-9. Molecular formula: C26H21F2N5O3. Mole weight: 489.47. | |
| FAD-AMP lyase (cyclizing) | Requires Mn2+ or Co2+. While FAD was the best substrate tested, the enzyme also splits ribonucleoside diphosphate-X compounds in which X is an acyclic or cyclic monosaccharide or derivative bearing an X-OH group that is able to attack internally the proximal phosphorus with the geometry necessary to form a P=X product; either a five-atom monocyclic phosphodiester or a cis-bicyclic phosphodiester-pyranose fusion. The reaction is strongly inhibited by ADP or ATP but is unaffected by the presence of the product, cFMN. Group: Enzymes. Synonyms: FMN cyclase; FAD AMP-lyase (cyclic-FMN-forming). Enzyme Commission Number: EC 4.6.1.15. CAS No. 208349-48-8. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-5352; FAD-AMP lyase (cyclizing); EC 4.6.1.15; 208349-48-8; FMN cyclase; FAD AMP-lyase (cyclic-FMN-forming). Cat No: EXWM-5352. |  |
| Altenusin, Penicillium sp. | Sphingomyelinase (N-SMase) and strong pp60c-Src inhibitor. Inhibits cFMS receptor tyrosine kinase (CSF-1/m-CSF receptor tyrosine kinase) which is implicated in cancer and bone diseases. Myosin light chain kinase inhibitor. Also exhibits anti-HIV-1 integrase activity. Group: Biochemicals. Grades: Highly Purified. CAS No. 31186-12-6. Pack Sizes: 1mg, 5mg. US Biological Life Sciences. | Worldwide |
Our database is helping our users find suppliers everyday.
